Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

novartis ag - NVS

NVS

Close Chg Chg %
121.74 1.20 0.99%

Closed Market

122.94

+1.20 (0.99%)

Volume: 1.18M

Last Updated:

Jul 9, 2025, 3:59 PM EDT

Trade Now

Company Overview: novartis ag - NVS

NVS Key Data

Open

$122.34

 Day Range

122.22 - 123.13

52 Week Range

96.06 - 124.45

 Market Cap

$230.90B

Shares Outstanding

1.90B

 Public Float

1.90B

Beta

0.59

 Rev. Per Employee

N/A

P/E Ratio

18.92

 EPS

$6.43

Yield

269.32%

 Dividend

$3.28

EX-DIVIDEND DATE

Mar 12, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.27M

  

NVS Performance

1 Week
 
 -0.18%
 
1 Month
 
 1.87%
 
3 Months
 
 13.17%
 
1 Year
 
 8.93%
 
5 Years
 
 47.56%
 

NVS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 25
Full Ratings ➔

About novartis ag - NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

NVS At a Glance

Novartis AG
Lichtstrasse 35
Basel, Basel-Stadt (Basle Town) 4056
Phone 41-61-324-11-11 Revenue 50.32B
Industry Pharmaceuticals: Major Net Income 11.94B
Sector Health Technology 2024 Sales Growth 10.733%
Fiscal Year-end 12 / 2025 Employees 75,883
View SEC Filings

NVS Valuation

P/E Current 18.986
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 16.448
Price to Sales Ratio 3.936
Price to Book Ratio 4.364
Price to Cash Flow Ratio 11.239
Enterprise Value to EBITDA 10.044
Enterprise Value to Sales 4.291
Total Debt to Enterprise Value 0.145

NVS Efficiency

Revenue/Employee 663,086.594
Income Per Employee 157,360.674
Receivables Turnover 6.128
Total Asset Turnover 0.478

NVS Liquidity

Current Ratio 1.035
Quick Ratio 0.836
Cash Ratio 0.469

NVS Profitability

Gross Margin 74.116
Operating Margin 30.66
Pretax Margin 27.184
Net Margin 23.732
Return on Assets 11.341
Return on Equity 26.327
Return on Total Capital 15.857
Return on Invested Capital 17.865

NVS Capital Structure

Total Debt to Total Equity 70.967
Total Debt to Total Capital 41.509
Total Debt to Total Assets 29.278
Long-Term Debt to Equity 52.068
Long-Term Debt to Total Capital 30.455
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Novartis Ag - NVS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
51.63B 50.55B 45.44B 50.32B
Sales Growth
+6.10% -2.09% -10.10% +10.73%
Cost of Goods Sold (COGS) incl D&A
15.87B 15.31B 12.57B 13.02B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
5.43B 5.45B 8.28B 6.07B
Depreciation
1.53B 1.46B 1.27B 1.19B
Amortization of Intangibles
3.90B 3.98B 7.01B 4.88B
COGS Growth
+4.93% -3.54% -17.86% +3.59%
Gross Income
35.76B 35.24B 32.87B 37.29B
Gross Income Growth
+6.62% -1.45% -6.73% +13.47%
Gross Profit Margin
+69.27% +69.72% +72.33% +74.12%
2021 2022 2023 2024 5-year trend
SG&A Expense
24.43B 23.14B 20.79B 21.87B
Research & Development
9.54B 8.88B 8.22B 9.30B
Other SG&A
14.89B 14.25B 12.57B 12.56B
SGA Growth
+7.02% -5.28% -10.14% +5.17%
Other Operating Expense
- (269.00M) (162.00M) 209.00M
Unusual Expense
684.00M 4.50B 3.60B 1.93B
EBIT after Unusual Expense
10.92B 7.76B 8.27B 13.50B
Non Operating Income/Expense
785.00M 1.65B 1.74B 1.21B
Non-Operating Interest Income
71.00M 379.00M 627.00M 568.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
905.00M 1.03B 873.00M 1.04B
Interest Expense Growth
-1.74% +13.92% -15.32% +18.79%
Gross Interest Expense
909.00M 1.04B 876.00M 1.04B
Interest Capitalized
4.00M 5.00M 3.00M 5.00M
Pretax Income
10.80B 8.38B 9.14B 13.68B
Pretax Income Growth
+17.31% -22.39% +9.02% +49.72%
Pretax Margin
+20.92% +16.58% +20.11% +27.18%
Income Tax
2.12B 1.42B 551.00M 1.70B
Income Tax - Current - Domestic
958.00M 617.00M 1.14B 897.00M
Income Tax - Current - Foreign
1.47B 1.45B 1.29B 1.49B
Income Tax - Deferred - Domestic
(23.00M) 142.00M (355.00M) 245.00M
Income Tax - Deferred - Foreign
(286.00M) (797.00M) (1.52B) (927.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
24.02B 6.96B 8.57B 11.94B
Minority Interest Expense
- (3.00M) 4.00M (2.00M)
Net Income
24.02B 6.96B 8.57B 11.94B
Net Income Growth
+197.58% -71.05% +23.19% +39.37%
Net Margin Growth
+46.53% +13.76% +18.86% +23.73%
Extraordinaries & Discontinued Operations
- - - 6.28B
-
Discontinued Operations
- - - 6.28B
-
Net Income After Extraordinaries
24.02B 6.96B 14.85B 11.94B
Preferred Dividends
- - - -
-
Net Income Available to Common
24.02B 6.96B 14.85B 11.94B
EPS (Basic)
10.7112 3.1886 7.1504 5.9164
EPS (Basic) Growth
+202.15% -70.23% +124.25% -17.26%
Basic Shares Outstanding
2.24B 2.18B 2.08B 2.02B
EPS (Diluted)
10.6288 3.1657 7.0985 5.8678
EPS (Diluted) Growth
+202.32% -70.22% +124.23% -17.34%
Diluted Shares Outstanding
2.26B 2.20B 2.09B 2.04B
EBITDA
17.03B 17.71B 20.14B 21.50B
EBITDA Growth
-1.46% +3.98% +13.75% +6.71%
EBITDA Margin
+32.99% +35.04% +44.33% +42.72%

Snapshot

Average Recommendation HOLD Average Target Price 123.186
Number of Ratings 25 Current Quarters Estimate 2.172
FY Report Date 09 / 2025 Current Year's Estimate 8.641
Last Quarter’s Earnings 2.35 Median PE on CY Estimate N/A
Year Ago Earnings 7.81 Next Fiscal Year Estimate 8.987
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 7 19 19
Mean Estimate 2.17 1.98 8.64 8.99
High Estimates 2.35 2.06 9.28 10.07
Low Estimate 2.04 1.73 7.51 7.93
Coefficient of Variance 5.02 6.00 4.84 6.66

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 3
OVERWEIGHT 1 1 1
HOLD 14 14 18
UNDERWEIGHT 2 2 0
SELL 4 4 4
MEAN Hold Hold Hold

Novartis Ag in the News